These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23707228)

  • 1. Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors.
    Tempestilli M; Gentilotti E; Tommasi C; Nicastri E; Martini F; De Nardo P; Narciso P; Pucillo LP
    Int Immunopharmacol; 2013 Aug; 16(4):492-7. PubMed ID: 23707228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.
    Ford J; Meaden ER; Hoggard PG; Dalton M; Newton P; Williams I; Khoo SH; Back DJ
    J Antimicrob Chemother; 2003 Sep; 52(3):354-8. PubMed ID: 12917239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
    Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
    Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption.
    Holmstock N; Mols R; Annaert P; Augustijns P
    Drug Metab Dispos; 2010 Sep; 38(9):1407-10. PubMed ID: 20551242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.
    Lee CG; Gottesman MM; Cardarelli CO; Ramachandra M; Jeang KT; Ambudkar SV; Pastan I; Dey S
    Biochemistry; 1998 Mar; 37(11):3594-601. PubMed ID: 9530286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
    Lucia MB; Rutella S; Leone G; Vella S; Cauda R
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darunavir: pharmacokinetics and drug interactions.
    Back D; Sekar V; Hoetelmans RM
    Antivir Ther; 2008; 13(1):1-13. PubMed ID: 18389894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
    de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
    Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
    Byakwaga H; Kelly M; Purcell DF; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA; Cooper DA; Emery S;
    J Infect Dis; 2011 Nov; 204(10):1532-40. PubMed ID: 21930607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
    Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
    J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
    Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
    Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.
    Minuesa G; Arimany-Nardi C; Erkizia I; Cedeño S; Moltó J; Clotet B; Pastor-Anglada M; Martinez-Picado J
    J Antimicrob Chemother; 2016 Oct; 71(10):2782-92. PubMed ID: 27334660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimens.
    Marsden MD; Krogstad PA; Zack JA
    Antivir Ther; 2012; 17(7):1375-9. PubMed ID: 22820096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of basal, substrate induced and total P-glycoprotein activity in bronchoalveolar lavage T-cell subsets.
    Donnenberg VS; Wilson JW; Burckart GJ; Zeevi A; Iacono A; Donnenberg AD
    Cytometry A; 2004 Feb; 57(2):75-85. PubMed ID: 14750128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein.
    Cianfriglia M; Dupuis ML; Molinari A; Verdoliva A; Costi R; Galluzzo CM; Andreotti M; Cara A; Di Santo R; Palmisano L
    Retrovirology; 2007 Mar; 4():17. PubMed ID: 17343726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of drug transporters on cellular resistance towards saquinavir and darunavir.
    König SK; Herzog M; Theile D; Zembruski N; Haefeli WE; Weiss J
    J Antimicrob Chemother; 2010 Nov; 65(11):2319-28. PubMed ID: 20817741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.